Branched-chain amino acids and type 2 diabetes: a bidirectional Mendelian randomization analysis.
Obesity (Silver Spring)
; 32(2): 423-435, 2024 Feb.
Article
em En
| MEDLINE
| ID: mdl-38269471
ABSTRACT
OBJECTIVE:
Genetic studies have suggested that the branched-chain amino acids (BCAAs) valine, leucine, and isoleucine have a causal association with type 2 diabetes (T2D). However, inferences are based on a limited number of genetic loci associated with BCAAs.METHODS:
Instrumental variables (IVs) for each BCAA were constructed and validated using large well-powered data sets and their association with T2D was tested using a two-sample inverse-variance weighted Mendelian randomization approach. Sensitivity analyses were performed to ensure the accuracy of the findings. A reverse association was assessed using instrumental variables for T2D.RESULTS:
Estimated effect sizes between BCAA IVs and T2D, excluding outliers, were as follows valine (ß = 0.14 change in log-odds per SD change in valine, 95% CI -0.06 to 0.33, p = 0.17), leucine (ß = 0.15, 95% CI -0.02 to 0.32, p = 0.09), and isoleucine (ß = 0.13, 95% CI -0.08 to 0.34, p = 0.24). In contrast, T2D IVs were positively associated with each BCAA, i.e., valine (ß = 0.08 per SD change in levels per log-odds change in T2D, 95% CI 0.05 to 0.10, p = 1.8 × 10-9 ), leucine (ß = 0.06, 95% CI 0.04 to 0.09, p = 4.5 × 10-8 ), and isoleucine (ß = 0.06, 95% CI 0.04 to 0.08, p = 2.8 × 10-8 ).CONCLUSIONS:
These data suggest that the BCAAs are not mediators of T2D risk but are biomarkers of diabetes.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Diabetes Mellitus Tipo 2
/
Aminoácidos de Cadeia Ramificada
Tipo de estudo:
Clinical_trials
Limite:
Humans
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article